メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
産婦人科学
医学部
医学部臨床教室
概要
フィンガープリント
ネットワーク
プロファイル
(22)
研究成果
(1077)
フィンガープリント
産婦人科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Endometrial Cancer
100%
Cervical Cancer
57%
Ovarian Cancer
48%
Gynecological Oncology
42%
Neoplasm
39%
Obstetrics
32%
Malignant Neoplasm
29%
Gynecology
29%
Female Genital Tract Cancer
25%
Overall Survival
22%
Gestational Diabetes
21%
Adenocarcinoma
20%
Disease
18%
Krukenberg Tumor
17%
Wart Virus
17%
Clinical Oncology
16%
Prognostic Factor
15%
Retroperitoneal Lymph Node Dissection
15%
Retrospective Study
14%
Cancer Cell
14%
COVID-19
14%
Cancer
13%
Lymph Node Metastasis
13%
Uterine Cancer
13%
Endometrium
13%
Hereditary Nonpolyposis Colorectal Cancer
12%
Paclitaxel
12%
Clear Cell Carcinoma
12%
Carboplatin
12%
Assisted Reproductive Technology
11%
Stem Cell
11%
Systematic Review
10%
Cervical Intraepithelial Neoplasia
10%
Endometrium Carcinoma
10%
Recurrent Disease
10%
Uterine Cervix
10%
Cervical Cancer Screening
10%
Radiation Therapy
10%
Pelvis
10%
Granulocyte Colony Stimulating Factor
10%
Pregnancy
10%
Biological Marker
10%
Breast Cancer
10%
Cervicectomy
9%
Carcinogenesis
9%
Diagnosis
9%
Immunotherapy
9%
Endometrial Hyperplasia
9%
Cytoreductive Surgery
9%
Clinical Trial
9%
Cisplatin
9%
Hazard Ratio
9%
Progenitor Cell
8%
Microsatellite Instability
8%
Hysterectomy
8%
Fallopian Tube
8%
Childbirth
8%
Neoadjuvant Chemotherapy
8%
BRCA1
8%
Progression Free Survival
8%
Cell Line
8%
Lymph Duct
8%
Survival Rate
8%
Magnetic Resonance Imaging
8%
Surgery
7%
Metastatic Carcinoma
7%
Adjuvant Chemotherapy
7%
Amniotic Stem Cell
7%
Debulking Surgery
7%
Cohort Analysis
7%
Cancer Registry
7%
Meta-Analysis
7%
Adverse Event
7%
In Vitro
7%
Fertility Preservation
6%
Prevalence
6%
Infection
6%
Recurrent Ovarian Cancer
6%
Human Papillomavirus Type 16
6%
Hysteroscopy
6%
Adjuvant Therapy
6%
Squamous Cell Carcinoma
6%
Primary Peritoneal Cancer
6%
Serous Carcinoma
6%
Endometriosis
6%
Bevacizumab
6%
Galactosyltransferase
6%
Dose Densification
6%
Oral Glucose Tolerance Test
6%
Sensitivity and Specificity
6%
Salpingooophorectomy
6%
Pembrolizumab
5%
Immune Checkpoint Inhibitor
5%
First Trimester Pregnancy
5%
DNA Methylation
5%
DNA Mismatch Repair
5%
Surgical Technique
5%
Vagina Reconstruction
5%
Surrogacy
5%
Carcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Endometrium Cancer
41%
Chemotherapy
36%
Ovary Cancer
35%
Malignant Neoplasm
33%
Uterine Cervix Cancer
26%
Neoplasm
19%
Paclitaxel
19%
Cisplatin
17%
Pregnancy Diabetes Mellitus
16%
Carboplatin
15%
Overall Survival
14%
Granulocyte Colony Stimulating Factor
13%
Female Genital Tract Cancer
12%
Ovary Carcinoma
12%
Disease
11%
Progression Free Survival
10%
Mouse
8%
Carcinoma
8%
Endometrium Carcinoma
8%
Adenocarcinoma
8%
Doxorubicin
7%
Galactosyltransferase
7%
Breast Cancer
7%
Retrospective Study
7%
Bevacizumab
6%
microRNA
6%
Clear Cell Carcinoma
6%
Peritoneum Cancer
6%
Biological Marker
6%
Macaca fascicularis
6%
Adverse Event
6%
Irinotecan
5%
Clinical Trial
5%
Febrile Neutropenia
5%
Pembrolizumab
5%
Hereditary Nonpolyposis Colorectal Cancer
5%
Docetaxel
5%
Uterine Cervix Carcinoma in Situ
5%
First-Line Chemotherapy
5%
Anticarcinogen
5%
Survival Rate
5%
Carcinogenesis
5%
Glycolipid
5%
Coronavirinae
5%
Drug Repositioning
5%
Recurrent Disease
5%
Keyphrases
Endometrial Cancer
39%
Japan
31%
Clinical Practice Guidelines
12%
Uterus Transplantation
12%
Ovarian Cancer
11%
Obstetrics and Gynaecology
10%
Overall Survival
10%
Granulocyte Colony-stimulating Factor (G-CSF)
10%
Gynecological Cancer
9%
Cervical Cancer
9%
Chemotherapy
8%
Cisplatin
8%
Confidence Interval
7%
Meta-analysis
7%
Japanese Patients
7%
Primary Prophylaxis
6%
Progression-free Survival
6%
Japan Society of Clinical Oncology
6%
Systematic Meta-analysis
6%
Gestational Diabetes Mellitus
6%
Cynomolgus Macaque
6%
Society of Gynecologic Oncology
6%
Japanese Gynecologic Oncology Group
5%
Paclitaxel
5%
Hazard Ratio
5%
Uterine Endometrial Cancer
5%